Weight Loss Drug Danuglipron May Bind to Cannabinoid Receptors Better Than THC
Molecular docking simulations suggest the oral GLP-1 weight loss drug danuglipron has higher binding affinity for CB1 and CB2 cannabinoid receptors than THC or the body's own endocannabinoids.
Quick Facts
What This Study Found
Danuglipron showed higher binding affinity for both CB1 and CB2 receptors than THC, anandamide, or 2-AG in computational docking experiments, suggesting potential cross-reactivity between GLP-1 receptor agonists and the endocannabinoid system.
Key Numbers
Danuglipron had higher binding affinity for CB1 and CB2 than any tested endogenous (2-AG, anandamide) or exogenous (THC) cannabinoid receptor ligand.
How They Did This
Computational molecular docking experiments comparing binding affinities of danuglipron, THC, anandamide, and 2-AG at GLP-1R, CB1, and CB2 receptors.
Why This Research Matters
Millions of people use GLP-1 drugs for weight loss, and millions use cannabis. If GLP-1 drugs interact with cannabinoid receptors, there could be unexpected effects or drug interactions that clinicians should know about.
The Bigger Picture
The GLP-1 and endocannabinoid systems both regulate appetite and reward. This computational study suggests they may share molecular targets, opening questions about whether GLP-1 drugs partially work through the endocannabinoid system.
What This Study Doesn't Tell Us
Computational docking study only; binding affinity in silico does not prove functional activity in living systems. No in vitro or in vivo validation. Danuglipron is an oral GLP-1 agonist not yet widely available.
Questions This Raises
- ?Does danuglipron actually activate or block cannabinoid receptors in living cells?
- ?Could GLP-1 drug side effects (appetite changes, mood effects) partly involve the endocannabinoid system?
- ?Should cannabis users on GLP-1 drugs be monitored for interactions?
Trust & Context
- Key Stat:
- Danuglipron bound CB1 and CB2 more strongly than THC in molecular docking
- Evidence Grade:
- Computational docking study without experimental validation; preliminary until confirmed in vitro and in vivo.
- Study Age:
- 2025 computational study
- Original Title:
- Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system.
- Published In:
- microPublication biology, 2025 (2025)
- Database ID:
- RTHC-06291
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Does this mean weight loss drugs affect the same system as cannabis?
The computational results suggest possible overlap, but this has not been confirmed in living systems. Molecular docking predicts binding potential but cannot confirm functional effects.
Should people using GLP-1 drugs avoid cannabis?
There is no clinical evidence of harmful interactions yet. This study raises a theoretical concern that requires laboratory and clinical investigation before any recommendations can be made.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-06291APA
Dailey, Kiersten A; Schneider, Lillian N; Petreaca, Ruben C; Yoder, Ryan J. (2025). Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system.. microPublication biology, 2025. https://doi.org/10.17912/micropub.biology.001690
MLA
Dailey, Kiersten A, et al. "Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system.." microPublication biology, 2025. https://doi.org/10.17912/micropub.biology.001690
RethinkTHC
RethinkTHC Research Database. "Molecular docking of danuglipron uncovers potential crossove..." RTHC-06291. Retrieved from https://rethinkthc.com/research/dailey-2025-molecular-docking-of-danuglipron
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.